Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

An AI tool appeared superior to two FDA-approved biomarkers for predicting how people with cancer will respond to immune ...

Given the success of the previous Research Topic 'Exploring Small Molecule Inhibitors in Cardiovascular and Cerebrovascular Diseases', we are pleased to ...

which a doctor may prescribe for someone with cancer. Most Medicare drug plans have a list of the drugs they cover. Depending on the circumstances, a person may receive chemotherapy drugs orally ...

The drug candidate targets Neuropathic Corneal Pain ... underscore OKYO Pharma's dedication to innovation and shareholder value. This article was generated with the support of AI and reviewed ...

Coaches, Schmidt said, have the power and visibility to relay a message about the value of cancer awareness. Coaches are some of the most visible people in college basketball. In some programs ...

DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Orphan Drugs was estimated at US$ ...

Scientists have developed a single-dose treatment for breast cancer that eliminates small tumors and significantly shrinks larger ones without side effects. Named ErSo-TFPy, this drug shows ...

Lisata Therapeutics (NASDAQ:LSTA) lost ~38% in the premarket on Wednesday after the cancer drug developer shared results from a mid-stage trial for its main asset, certepetide, in patients with ...

Geoffrey Joyce, the director of Health Policy at the University of Southern California's Schaeffer Center for Health Policy & Economics, told Newsweek that the $2 Medicare drug list model that ...

Although these drugs are better tolerated than chemotherapy, they still have side effects that diminish quality of life and can leave people at risk for cancer recurrence and treatment resistance.

Cancer drug sales drive J&J Q4 revenue, profit Forecasts 2025 earnings above Wall Street estimates Currency impact of 25c/share for 2025 surprises investors Shares drop 4% in early trading J&J has ...